IL6 and type 2 diabetes mellitus: Results remained robust after adjustment for other inflammation (interleukin 6), renal and cardiac (creatinine, NT-proBNP, cardiac troponin T) biomarkers, and after excluding participants with CVD, type 2 diabetes, and obesity.